Literature DB >> 12947097

Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity.

Kevin H Mayo1, Ruud P M Dings, Carolee Flader, Irina Nesmelova, Balasz Hargittai, Daisy W J van der Schaft, Loes I van Eijk, Dinesha Walek, Judy Haseman, Thomas R Hoye, Arjan W Griffioen.   

Abstract

Based on structure-activity relationships of the angiostatic beta-sheet-forming peptide anginex, we have designed a mimetic, 6DBF7, which inhibits angiogenesis and tumor growth in mice. 6DBF7 is composed of a beta-sheet-inducing dibenzofuran (DBF)-turn mimetic and two short key amino acid sequences from anginex. This novel antiangiogenic molecule is more effective in vivo than parent anginex. In a mouse xenograft model for ovarian carcinoma, 6DBF7 is observed to reduce tumor growth by up to 80%. It is suggested that the activity is based on antiangiogenesis, because in vitro tube formation is inhibited, and because treatment of tumor-bearing mice led to a significant reduction in microvessel density within the tumor. This partial peptide mimetic is the first endothelial cell-specific molecule designed as a substitute for an angiostatic inhibitory peptide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947097     DOI: 10.1074/jbc.M308608200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Structure-activity relationships of the human prothrombin kringle-2 peptide derivative NSA9: anti-proliferative activity and cellular internalization.

Authors:  Hyun Sook Hwang; Dong Won Kim; Soung Soo Kim
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

2.  Conformationally constrained peptides from CD2 to modulate protein-protein interactions between CD2 and CD58.

Authors:  Ameya Gokhale; Thomas K Weldeghiorghis; Veena Taneja; Seetharama D Satyanarayanajois
Journal:  J Med Chem       Date:  2011-07-14       Impact factor: 7.446

3.  Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.

Authors:  Sashikanth Banappagari; Sharon Ronald; Seetharama D Satyanarayanajois
Journal:  Medchemcomm       Date:  2011-01-01       Impact factor: 3.597

4.  Inhibition of cell adhesion and immune responses in the mouse model of collagen-induced arthritis with a peptidomimetic that blocks CD2-CD58 interface interactions.

Authors:  Ameya S Gokhale; Rushikesh Sable; Jason D Walker; Leslie McLaughlin; Konstantin G Kousoulas; Seetharama D Jois
Journal:  Biopolymers       Date:  2015-11       Impact factor: 2.505

5.  CLT1 targets angiogenic endothelium through CLIC1 and fibronectin.

Authors:  Lynn M Knowles; Gunjan Malik; Brian L Hood; Thomas P Conrads; Jan Pilch
Journal:  Angiogenesis       Date:  2011-12-28       Impact factor: 9.596

6.  A peptide from the beta-strand region of CD2 protein that inhibits cell adhesion and suppresses arthritis in a mouse model.

Authors:  Seetharama D Satyanarayanajois; Barlas Büyüktimkin; Ameya Gokhale; Sharon Ronald; Teruna J Siahaan; John R Latendresse
Journal:  Chem Biol Drug Des       Date:  2010-06-23       Impact factor: 2.817

7.  Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.

Authors:  Ruud P M Dings; Nigam Kumar; Michelle C Miller; Melissa Loren; Huzaifa Rangwala; Thomas R Hoye; Kevin H Mayo
Journal:  J Pharmacol Exp Ther       Date:  2012-12-11       Impact factor: 4.030

8.  NMR solution structure of the angiostatic peptide anginex.

Authors:  Monica M Arroyo; Kevin H Mayo
Journal:  Biochim Biophys Acta       Date:  2007-03-24

9.  Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.

Authors:  Ruud P M Dings; Joseph I Levine; Susan G Brown; Lucile Astorgues-Xerri; John R MacDonald; Thomas R Hoye; Eric Raymond; Kevin H Mayo
Journal:  Invest New Drugs       Date:  2013-02-08       Impact factor: 3.850

10.  Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.

Authors:  Ruud P M Dings; Emily S Van Laar; Jeremy Webber; Yan Zhang; Robert J Griffin; Stephen J Waters; John R MacDonald; Kevin H Mayo
Journal:  Cancer Lett       Date:  2008-04-01       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.